What to Know About GLP-1 Medications and Weight Management Programs
Learn how Eden connects patients to licensed providers to explore GLP-1 medications as part of medical weight management programs.
Learn what affects GLP-1 injection costs—including Ozempic®, Wegovy®, and Rybelsus®—plus insurance tips, savings options, and licensed healthcare access via Eden.
Semaglutide is a GLP-1 receptor agonist that helps manage:
Semaglutide is FDA-approved for type 2 diabetes (Ozempic®, Rybelsus®) and chronic weight management in individuals with obesity or overweight with related conditions (Wegovy®). These medications work through GLP-1 receptor activity and must be prescribed and monitored by a licensed healthcare provider.
Explore GLP-1 medication options with licensed healthcare providers whom you may connect with via Eden’s platform.
Prices reflect typical U.S. retail costs without discounts or insurance and may vary by dose.
Medicare generally does not cover semaglutide for weight management unless prescribed for type 2 diabetes. Medicaid eligibility and coverage vary by state.
Novo Nordisk may offer savings programs for eligible commercially insured patients:
Individuals without commercial insurance may qualify for income-based assistance programs.
Some studies suggest that GLP-1 therapy may have long-term health benefits for individuals with diabetes or obesity; consult with a licensed provider to understand what treatment may be appropriate for your health profile. (PubMed, 2019).
The average cost of GLP-1 injections varies widely, from $900 to $1,800/month without insurance to under $300/month with coverage or compounding access. Factors such as brand, dosage, and insurance eligibility significantly affect pricing.
For safe, cost-effective access, work with a licensed healthcare provider who may:
Eden connects users with vetted healthcare professionals and supports the treatment journey from start to finish.
Explore your GLP-1 treatment options
This article is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider for medical guidance and speak with your insurance provider to understand your coverage options. Eden does not practice medicine or dispense medications. Eden connects users with licensed healthcare providers who determine treatment eligibility and refer prescriptions to accredited pharmacies.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Depending on the dose and formulation, it ranges from $900 to $1,800.
Only for type 2 diabetes. Wegovy® for weight loss is excluded from Medicare Part D.
No. Manufacturer copay programs are only available to individuals with commercial insurance. Patients on Medicare or Medicaid may need to explore alternative savings or support programs.
No. Semaglutide remains under patent protection, with expiration dates ranging from 2026 to 2033 depending on the product (e.g., Ozempic®, Wegovy®, Rybelsus®). Until then, only brand-name versions are available.